Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications Including Bronchial and Thymic Neuroendocrine Tumour, Paraganglioma/Phaeochromocytoma, Medullary Thyroid Carcinoma, and Repeat Peptide Receptor Radionuclide Therapy

NCT06121271 is registered in ClinicalTrials.gov with University College, London as lead sponsor.

NCT NCT06121271
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06121271 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications Including Bronchial and Thymic Neuroendocrine Tumour, Paraganglioma/Phaeochromocytoma, Medullary Thyroid Carcinoma, and Repeat Peptide Receptor Radionuclide Therapy
Lead sponsor
University College, London
Phase
Phase 2
Overall status
Not yet recruiting
Start date
December 18, 2023
Completion date
November 6, 2027
Enrollment
110 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

bronchial and thymic neuroendocrine tumour, medullary thyroid carcinoma, paraganglioma/ phaeochromocytoma, those requiring repeat peptide receptor radionuclide therapy